Parameter Set Antiepileptic Drugs All-in-One Method - LC-MS/MS

Order No.: 92921/XT
Parameters:
10,11-Dihydroxycarbamazepine, 10-OH-Carbamazepine, Brivaracetam, Carbamazepine, Carbamazepine-10,11-epoxide, Ethosuximide, Felbamate, Gabapentin, Lacosamide, Lamotrigine, Levetiracetam (Keppra®), N-Desmethylmesuximide, Oxcarbamazepine, Perampanel, Phenobarbital, Phenylethylmalonamide (PEMA), Phenytoin, Pregabalin, Primidone, Retigabine, Rufinamide, Stiripentol, Sultiame, Theophylline, Tiagabine, Topiramate, Valproic Acid, Vigabatrin, Zonisamide

Determination of all 29 analytes in a single run
With 26 internal standards
Part of the MassTox® TDM Series A

CE-IVD validated product ready for IVDR within timeframes and transition periods specified by the IVDR 2017/746

Brivaracetam

Carbamazepine

Carbamazepine-10,11-epoxide

10,11-Dihydroxycarbamazepine

10-OH-Carbamazepine

Ethosuximide

Felbamate

Gabapentin

Lacosamide

Lamotrigine

Levetiracetam (Keppra®)

N-Desmethylmesuximide

Oxcarbazepine

Perampanel

Phenobarbital

Phenylethylmalonamide (PEMA)

Phenytoin

Pregabalin

Primidone

Retigabine

Rufinamide

Stiripentol

Sultiame

Theophylline

Tiagabine

Topiramate

Valproic acid

Vigabatrin

Zonisamide

Clinical relevance

Epileptic seizures are the result of synchronous discharges of neuron groups in the brain that can lead to sudden and involuntary stereotypical behavioural or sensory disorders. Numerous types of seizures have been described, each of which requires specialised therapy. The probability of them occurring depends on a number of factors. In addition to genetic predisposition, it is primarily exogenous factors that are relevant, such as accident, thrombosis, tumours or meningitis. Therapy with anticonvulsive medication (antiepileptics) leads to a reduction in seizures and sometimes even a complete elimination of seizures in most treated patients. The precondition for the antiepileptics to have a therapeutic effect is usually patient compliance, which means regular use of the medication. Thus, monitoring of the blood levels is essential, especially during initial dose setting.

 

Product advantages

  • Also including brivaracetam, perampanel, retigabine
  • Determination of all analytes in a single run
  • With 26 internal standards

With the Parameter Set Antiepileptic Drugs in serum/plasma, 29 different drugs can be measured quickly and efficiently using LC-MS/MS. Due to the careful optimisation of all kit components as well as the chromatographic separation, matrix effects (“ion suppression”) are minimised and the robustness of the method is enhanced. Sample preparation is based on a protein precipitation step. The use of stable isotopically labelled (deuterated) and co-eluting internal standards as well as 3PLUS1® multilevel calibrators ensures high precision and the reproducible and reliable quantification of the analytes. The method is comprehensively validated.

The Parameter Set is a part of the Series A modular system, which enables the analysis of all parameters without switching column or changing the mobile phases, thereby minimising required workload in the laboratory. The Basic Kit A contains all components required for sample preparation and all necessary mobile phases. The MasterColumn® A is the analytical column used for the determination of all Series A analytes. Our portfolio contains further MassTox® Parameter Sets.

For the analysis you require the MassTox® TDM Basic Kit A, the specific MassTox® TDM Parameter Set and the analytical column MassTox® TDM MasterColumn® A.

More Information
Method of Analysis LC-MS/MS
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Lower Limit of Quantitation 0.004 – 9 mg/l
Upper Limit of Quantification up to 0.50 – 275 mg/l
Intraassay CV < 10 %
Interassay CV < 13 %
Recovery 84 – 118 %
Sample Preparation
  • Add 800 µl Internal Standard Mix to 12 ml Precipitation Reagent (= mixture A).
  • Pipette 50 µl sample/calibrator/MassCheck® control into a 1.5 ml reaction vial.
  • Add 25 µl Extraction Buffer, mix briefly (vortex) and incubate 2 min.
  • Add 250 µl of mixture A, mix 30 s (vortex) and centrifuge 5 min.
  • Dilute supernatant with Dilution Buffer (depending on instrument sensitivity) and inject into LC-MS/MS system.
Run Time 4.9 min
Injection Volume 0.2 – 30 µl
Gradient binary
Ionisation ESI positive and negative
MS/MS Mode MRM
Additional Info

This method further includes 26 internal standards, which are not shown in the chromatogram for clarity.

To avoid ESI switching, the analysis of ethosuximide, phenobarbital and valproic acid can be performed separately in ESI negative mode.

Parameters 10,11-Dihydroxycarbamazepine, 10-OH-Carbamazepine, Brivaracetam, Carbamazepine, Carbamazepine-10,11-epoxide, Ethosuximide, Felbamate, Gabapentin, Lacosamide, Lamotrigine, Levetiracetam (Keppra®), N-Desmethylmesuximide, Oxcarbamazepine, Perampanel, Phenobarbital, Phenylethylmalonamide (PEMA), Phenytoin, Pregabalin, Primidone, Retigabine, Rufinamide, Stiripentol, Sultiame, Theophylline, Tiagabine, Topiramate, Valproic Acid, Vigabatrin, Zonisamide
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
As a customer please login or register to gain full access.

Brivaracetam

Carbamazepine

Carbamazepine-10,11-epoxide

10,11-Dihydroxycarbamazepine

10-OH-Carbamazepine

Ethosuximide

Felbamate

Gabapentin

Lacosamide

Lamotrigine

Levetiracetam (Keppra®)

N-Desmethylmesuximide

Oxcarbazepine

Perampanel

Phenobarbital

Phenylethylmalonamide (PEMA)

Phenytoin

Pregabalin

Primidone

Retigabine

Rufinamide

Stiripentol

Sultiame

Theophylline

Tiagabine

Topiramate

Valproic acid

Vigabatrin

Zonisamide

Clinical relevance

Epileptic seizures are the result of synchronous discharges of neuron groups in the brain that can lead to sudden and involuntary stereotypical behavioural or sensory disorders. Numerous types of seizures have been described, each of which requires specialised therapy. The probability of them occurring depends on a number of factors. In addition to genetic predisposition, it is primarily exogenous factors that are relevant, such as accident, thrombosis, tumours or meningitis. Therapy with anticonvulsive medication (antiepileptics) leads to a reduction in seizures and sometimes even a complete elimination of seizures in most treated patients. The precondition for the antiepileptics to have a therapeutic effect is usually patient compliance, which means regular use of the medication. Thus, monitoring of the blood levels is essential, especially during initial dose setting.

 

Product advantages

  • Also including brivaracetam, perampanel, retigabine
  • Determination of all analytes in a single run
  • With 26 internal standards

With the Parameter Set Antiepileptic Drugs in serum/plasma, 29 different drugs can be measured quickly and efficiently using LC-MS/MS. Due to the careful optimisation of all kit components as well as the chromatographic separation, matrix effects (“ion suppression”) are minimised and the robustness of the method is enhanced. Sample preparation is based on a protein precipitation step. The use of stable isotopically labelled (deuterated) and co-eluting internal standards as well as 3PLUS1® multilevel calibrators ensures high precision and the reproducible and reliable quantification of the analytes. The method is comprehensively validated.

The Parameter Set is a part of the Series A modular system, which enables the analysis of all parameters without switching column or changing the mobile phases, thereby minimising required workload in the laboratory. The Basic Kit A contains all components required for sample preparation and all necessary mobile phases. The MasterColumn® A is the analytical column used for the determination of all Series A analytes. Our portfolio contains further MassTox® Parameter Sets.

For the analysis you require the MassTox® TDM Basic Kit A, the specific MassTox® TDM Parameter Set and the analytical column MassTox® TDM MasterColumn® A.

More Information
Method of Analysis LC-MS/MS
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Lower Limit of Quantitation 0.004 – 9 mg/l
Upper Limit of Quantification up to 0.50 – 275 mg/l
Intraassay CV < 10 %
Interassay CV < 13 %
Recovery 84 – 118 %
Sample Preparation
  • Add 800 µl Internal Standard Mix to 12 ml Precipitation Reagent (= mixture A).
  • Pipette 50 µl sample/calibrator/MassCheck® control into a 1.5 ml reaction vial.
  • Add 25 µl Extraction Buffer, mix briefly (vortex) and incubate 2 min.
  • Add 250 µl of mixture A, mix 30 s (vortex) and centrifuge 5 min.
  • Dilute supernatant with Dilution Buffer (depending on instrument sensitivity) and inject into LC-MS/MS system.
Run Time 4.9 min
Injection Volume 0.2 – 30 µl
Gradient binary
Ionisation ESI positive and negative
MS/MS Mode MRM
Additional Info

This method further includes 26 internal standards, which are not shown in the chromatogram for clarity.

To avoid ESI switching, the analysis of ethosuximide, phenobarbital and valproic acid can be performed separately in ESI negative mode.

Parameters 10,11-Dihydroxycarbamazepine, 10-OH-Carbamazepine, Brivaracetam, Carbamazepine, Carbamazepine-10,11-epoxide, Ethosuximide, Felbamate, Gabapentin, Lacosamide, Lamotrigine, Levetiracetam (Keppra®), N-Desmethylmesuximide, Oxcarbamazepine, Perampanel, Phenobarbital, Phenylethylmalonamide (PEMA), Phenytoin, Pregabalin, Primidone, Retigabine, Rufinamide, Stiripentol, Sultiame, Theophylline, Tiagabine, Topiramate, Valproic Acid, Vigabatrin, Zonisamide
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
As a customer please login or register to gain full access.